This study examined the effect of 2 yr of treatment with the aminobisphosphonate alendronate (ALN) (0.05 or 0.25 mg/ kg i.v. ALN every 2 wk) on estrogen deficiency bone loss and bone strength changes in ovariectomized (OVX) baboons (n = 7 per group) and the ALN mode of action at the tissue level. Biochemical markers of bone turnover increased in OVX animals and were maintained by ALN treatment at non-OVX levels (low dose) or below (high dose). 2 yr of treatment produced no cumulative effects on bone turnover markers. Histomorphometry showed a marked increase in cancellous bone remodeling in OVX animals. Activation frequency increased from 0.48 to 0.86 per yr (L5 vertebra), and the osteoid surfaces from 9 to 13.5% (P < 0.05). No changes were observed in eroded and osteoclast surfaces. ALN treatment decreased activation frequency and indices of bone formation to control levels (low dose) or below (high dose), did not change indices of mineralization, and increased bone mineral density (BMD) in the lumbar vertebrae (L2-L4) by 15% at 0.25 mg/kg (P < 0.05), relative to vehicle-treated animals. The mean strength of cancellous bone (LA) increased by 44% (low ALN dose) and 100% (high dose), compared with vehicle. The strength of individual bones correlated with the square of the L2-L4 BMD (r = 0.91, P < 0.0034). In conclusion, ALN treatment reversed the effects of ovariectomy on cancellous bone turnover and increased bone mass and bone strength in baboons. (J. Clin. Invest. 1993. 92:2577-2586 Key words: osteoporosis * alendronate * histomorphometry-bone strength * bone mineral density
Introduction
Osteoporosis is a reduction in bone mass associated with an increased risk of fractures (1) (2) (3) (4) (5) (6) (7) (8) . While the treatment of established osteoporosis is still controversial (9, 10) , there is good indication that osteoporosis can be prevented (1 1-14) . The increase in bone turnover, associated with loss of ovarian function, is quantitatively the most important contributing factor to bone loss in osteoporosis (15) (16) (17) (18) (19) (20) . A rational approach to prevention, other than estrogen replacement therapy, is therefore treatment that reduces bone resorption and bone turnover. Bisphosphonates are nonhydrolyzable, pyrophosphate analogues that bind to the hydroxyapatite in bone, by virtue of their bisphosphonate structure, and inhibit bone resorption (21 ) . Aminobisphosphonates are among the most potent agents in this group (22) . Alendronate sodium (ALN),2 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid, trihydrate sodium salt, was shown to inhibit bone resorption in rats subjected to immobilization (23, 24) or estrogen deficiency (25) and in patients with Paget's disease (26) and postmenopausal osteoporosis (27) .
The objective of this study was to evaluate the efficacy of the aminobisphosphonate ALN in preventing the bone loss caused by estrogen deficiency in a nonhuman primate model. Rats, dogs, sheep, pigs, and primates have been reported to lose bone after ovariectomy (28) (29) (30) (31) (32) (33) (34) (35) (36) . We chose to study the ovariectomized baboon since baboons are relatively large primates, have menstrual cycles similar to humans, thus similar estrogen exposure, and exhibit intracortical Haversian remodeling. This enabled us to study the effects ofovariectomy and treatment at the tissue level in the context of bone changes similar to those produced by estrogen deficiency in humans. Animals were treated for 2 yr with two doses of ALN. Biochemical parameters of bone turnover, bone mineral density, and bone biopsies were evaluated at 3-, 6-, or 12-mo intervals. The effects oftreatment up to 12 mo in living baboons have been previously reported (37) . At death, we carried out histomorphometric analysis of iliac crest as well as vertebrae and ex vivo measurements of bone strength in vertebrae and femora. The results obtained show that ALN treatment reverses the skeletal effects ofovariectomy and may be useful therapy for the prevention of postmenopausal bone loss.
Methods
28 adult female baboons (Papio anubis) weighing -14 kg were used in this study. Animals were fed standard laboratory food (Purina Monkey Chow) and fruit. All animals had a history of regular menstrual sure, to confirm adult skeletal status, and to confirm the absence of skeletal abnormalities. Animals were assigned to one of four groups (n = 7/group) on the basis of body weight. Animals were housed and treated according to the U.S. Department of Agriculture guidelines for humane animal treatment. Ovariectomy (OVX). Three groups ofbaboons (n = 21 ) underwent surgery to remove the ovaries and uterus (OVX groups) as described in detail in Thompson et al. (37) . All animals recovered from surgery without incident. The fourth group with intact ovaries was not exposed to surgery (non-OVX group).
Treatment with ALN. The ovariectomized baboons were treated with 0, 0.05, or 0.25 mg ALN/kg i.v. every 2 wk. Under anesthesia, a catheter was inserted in the saphenous vein and 3 ml of saline with or without ALN was infused over 3 min. The baboons were killed after 2 yr oftreatment. The weight ofeach animal was recorded. The effectiveness of ovariectomy was verified by inspection ofthe uterus for involutional atrophy. The spine and femora were harvested immediately and kept frozen at -20'C for mechanical testing.
Serum and urine biochemistry. Bone histomorphometry. All baboons were injected with calcein (10 mg/kg i.v.) 22 and 8 d before death. At death the whole iliac crest was excised and fixed in 10% formalin. Wedge biopsies 1 cm in length were taken -2 cm below the postero-superior iliac spine. The first and fifth lumbar vertebrae were embedded in methylmethacrylate without prior decalcification (40) . Sections of6-10 gm thickness were cut with a Polycut S microtome (Reichert Jung, Heidelberg, Germany) and examined without further staining for dynamic histomorphometry or stained with toluidine blue and Masson's trichrome for static measurements. All morphometric measurements of bone remodeling were carried out in cancellous bone with semiautomatic image analysis system (System IV; Bioquant, Nashville, TN). Cancellous bone was demarcated from cortical bone following published criteria (41 The length of one randomly selected femur from each animal was measured from the intercondylar notch to the piriformis fossae. The condyles were removed and the supracondylar and subtrochanteric regions of the diaphysis were embedded in square aluminum tubing with polymethylmethacrylate. These loading fixtures were placed 42.3 mm from the midpoint of the femur, and the femora were then tested to failure in three-point bending with the upper loading point aligned with the midpoint of the posterior surface. The load and displacement at failure were recorded and the bending stiffness was calculated from the linear portion of the load vs. displacement curve.
The femur distal to the subtrochanteric fixture was then removed and the neck was tested to failure in simulated single-legged stance. The load was applied to the femoral head, parallel to the axis ofthe diaphysis, through an aluminum cup lined with polymethylmethacrylate. The load and displacement at failure were recorded and the bending stiffness was calculated.
The contralateral femur provided transverse sections of cortical bone from the proximal diaphysis, cortical beams from the mid-diaphysis, and cylinders of trabecular bone from the femoral neck for testing. A transverse section, 1 mm in width, was taken from a standard location in each proximal femoral diaphysis with an Isomet low-speed diamond saw (Buehler, Lake Bluff, IL). The cross-sectional areas of both cortical bone and the medullary canal were measured and the maximum and minimum moments of inertia were determined from digitized images using the interactive computer software package (SLICE) and an image processing system (FD-5000; Gould, San Jose, CA). A cylinder of cortical bone was then obtained from a standard location along the central diaphysis. Cortical beams were cut from the anterior, posterior-medial, and lateral quadrants of the cylinder. The specimens were sanded manually to remove the periosteum and to create true beams (2.2 X 2.2 X 22 mm). These beams were then tested to failure in three-point bending. The load and displacement at failure were recorded and the bending stiffness was calculated. A diamond coring tool (3.4-mm internal diameter; Starlite, Rosemont, PA) was used to remove a cylinder of trabecular bone strength from a standard location within each femoral neck. The cylinders were cut to a length of 3.4 mm and were then compressed to failure. The elastic modulus and the strength were recorded. The cylinders were then defatted with a combination of ultrasonic bleaching and a water jet. The apparent density (hydrated weight divided by the volume ofthe intact specimen) and tissue density (hydrated weight divided by the hydrated weight minus the submerged-weight) were determined by the method previously described by Carter and Hayes (44).
The superior and inferior endplates of the L3 vertebrae were embedded in polymethylmethacrylate to create plano-parallel surfaces for testing. The vertebrae were then compressed to failure, the load and displacement at failure were recorded, and the bending stiffness was calculated. The vertebrae were then separated from the polymethylmethacrylate, and anteroposterior, lateral, and cephalocaudad radiographs were taken to identify any fractures through the endplates.
A cylinder of trabecular bone, 5.1 mm in diameter and oriented along the cephalocaudad axis, was removed from the geometric center ofthe L4 vertebrae. From each cylinder, two smaller cylinders, each 5.1 mm in length, were created. One cylinder contained dense trabecular bone inferior to the superior endplate, and the second contained less dense bone from the midbody. The cylinders were compressed to failure, and the elastic modulus and the strength were recorded. The cylinders were then defatted with a combination ofultrasonic bleaching and a water jet, and the apparent density, tissue density, and ash content were determined.
Statistical analysis. Means and standard deviation were computed for each variable for each time point of the study. One-way ANOVA was performed and significance was established at P < 0.05. Intergroup comparisons were performed with the Fisher-protected least significant difference (PLSD) test. Differences between treatment group means greater than PLSD indicate significance. Linear regression analysis between biochemical markers and bone histology, and bone histology and bone density were done with Abacus Concepts Statview (Abacus Concepts Inc., Berkeley, CA).
Equality of group variances was tested with Levene's test. A oneway ANOVA was used with dose level as the grouping variable if the group variances were equal. If Levene's test indicated unequal variances, then Brown-Forsythe statistics were computed with the same grouping variable. Ifthe grouping variable was shown to have a significant impact on the outcome variable ofinterest, then multiple comparison tests were performed with the Tukey method. Group differences were considered significant at P < 0.05.
Results
Biochemical parameters. Measurements of biochemical markers of bone formation and resorption are shown in Fig. 1, A-D. Serum AP (Fig. 1 A) , BGP ( Fig. 1 B) , and TRAP ( Fig. 1  C) were significantly elevated in OVX vehicle-treated animals, relative to non-OVX at 3 and 6 mo, and remained elevated throughout the study. ALN treatment maintained the value of these parameters at control non-OVX levels (lower dose) or below controls (higher dose, at some time points). The excretion ofthe bone collagen crosslink lysylpyridinoline/creatinine (Fig. 1 D) was significantly elevated in the OVX vehicletreated animals, relative to non-OVX throughout the study, starting at 3 mo. At all time points ALN treatment reduced the excretion of lysylpyridinoline to non-OVX levels. There were no significant differences between the two doses of ALN, although the values were usually lower for the high dose. The suppression of bone resorption reached a steady state at 3 mo and did not increase with time during the 2 yr of treatment. Both parameters of bone resorption declined after 9-12 mo in OVX-vehicle treated animals, suggesting a relative decrease in the overall bone resorption of the skeleton. The parameters of bone formation declined less (BGP) or not detectably (alkaline phosphatase), consistent with the longer duration of the formation phase in bone remodeling. Serum calcium, phosphate, parathyroid hormone calcitonin, and urinary calcium/creatine (Ca/Cr) and phosphate/creatinine (Pi/Cr) ratios at 2 yr post-OVX showed no systematic changes as a function oftreatment (Table I ). The urinary Ca/Cr and Pi/Cr values varied widely among animals (the SD was -100%) and no statistically significant differences among the groups were recorded.
Histomorphometry. Indices for iliac crest cancellous bone histomorphometry, after 2 yr of treatment, are summarized in Table II . The bone volume was not statistically different between non-OVX, OVX vehicle, and OVX low-dose ALN animals, but it was significantly increased in animals receiving high-dose ALN. The activation frequency (Ac.f), which estimates the frequency of initiation of remodeling cycles on the bone surface, was increased twofold in OVX vehicle animals Table IV presents indices ofbone remodeling in the lumbar were found in BFR/BS and OS/BS, which also reflect tissue vertebra. Consistent with the results observed in iliac crest, aclevel bone turnover. The mean values for osteoid thickness and tivation frequency and the various indices of bone turnover mineral apposition rate were higher in the OVX vehicle ani-(OS/BS, MS/BS, BFR/BS BFR/BV) were still significantly mals, and no differences were observed between the ALNelevated in the untreated animals 2 yr after ovariectomy. These treated and non-OVX animals. In none of the specimens was parameters were decreased by ALN treatment in a dose-depenthe mean osteoid thickness, corrected for section obliquity, dent manner. Bone formation, expressed per unit of bone sur-> 12.5 gm. No significant changes were found in either the face (BFR/BS) and as %/yr (BFR/BV), was not significantly active formation period or in mineralization lag time between different between the higher and the lower ALN dose. No signifthe various groups. icant differences due to ovariectomy or treatment were obTable III presents indices oftrabecular structure in the fifth served in the number of multinucleated osteoclasts per unit lumbar vertebra. Bone volume was slightly reduced in the bone surface, the extent of eroded surfaces, the osteoid thick-OVX vehicle as compared with non-OVX (not statistically sig-ness, or the mineral apposition rate. nificant). Treatment with ALN (both doses) resulted in signifiBone mineral density. Table V presents the bone density cant bone gain. The increase in bone volume produced by measurements. Radial BMD, which measures almost exclu-ALN can be accounted for by a significant thickening of the sively cortical bone, showed no statistically significant differtrabeculae rather than by changes in trabecular number (denences between the groups. Femoral neck BMD was signifisity).
cantly higher in animals treated with high-dose ALN as com- pared with controls. BMD of the lumbar spine showed a significant reduction of -13% in the OVX vehicle group and a dose-dependent increase to non-OVX levels by ALN treatment. For the high dose, BMD was 15% higher than the OVX vehicle (P < 0.03).
The apparent density (mg/cm3) of L4 cancellous bone decreased by 17% in OVX vehicle relative to non-OVX. This reduction was fully prevented by low-dose ALN, and there was a 62% increase with high-dose ALN, relative to OVX vehicle.
A close correlation was observed between histomorphometric and biochemical parameters of bone turnover as well as BMD. The osteoid surface measured in the iliac crest showed a highly significant positive correlation (r = + 0.81, P < 0.0001 ) with serum osteocalcin levels (Fig. 2 A) . The bone mineral density in the lumbar vertebrae (average of L2-L4) showed a statistically significant negative correlation with the bone turnover rate in the iliac crest (Fig. 2 B) , consistent with the notion that bone loss caused by estrogen deficiency is related to increased bone turnover.
Biomechanical measurements. The results of mechanical testing are summarized in Table VI . There were no differences among groups in mean body weights at death. The stiffness and failure load for the femoral midshaft and the neck did not differ among treatment groups. Neither the area measurements of the cortical bone and the medullary canal nor the inertial properties varied among groups. There were no differences among groups in stiffness or failure load of cortical beam specimens tested to failure in three-point bending. In addition, the modulus and strength oftrabecular cylinders taken from the femoral neck did not vary significantly among groups. There were also no differences among groups in apparent density, tissue density, or ash content.
The data from six L3 vertebrae compressed to failure were excluded from analysis due to fracture through the endplates. 8 MPa). The strength of the cylinders taken inferior to the endplates also varied among groups. The strength of the high-dose group was two times greater than the vehicle-treated group and greater than the control group ( 18 vs. 9 and 11 MPa, respectively).
The apparent density ofthe trabecular cylinders taken from the midbody and endbody regions of L4 varied among treatment groups. The density of the endbody cylinders from animals given high-dose treatment was greater than those treated with vehicle (0.592 vs. 0.365 gm/cm3). The density ofthe midbody cylinders from animals given high dose was greater than control and vehicle-treated groups (0.400 vs. 0.236 and 0.235 gm/cm3, respectively). Tissue density did not vary among groups in either the midbody or endbody cylinders. Ash con- 1.1 tent per dry weight of the midbody cylinders was not significantly different among groups. The cylinders from the endplate region did not differ in ash content among groups either. Fig. 3 A depicts the correlation between in vivo measurements of BMD by dual-photon absorptiometry and ultimate strength of the L4 vertebral core. A highly significant positive correlation (r = 0.94, P < 0.003) is present. Fig. 3 B shows the linear regression analysis between trabecular thickness (Tb.Th.) and the ultimate strength (r = 0.63, P < 0.0005), which also shows a strong positive correlation.
Discussion
Although the molecular basis for estrogen deficiency-mediated bone loss is not fully understood, it is well established that estrogen deficiency after artificial ( 16, 45) or natural menopause ( 18, 46, 47) causes an increase in bone turnover at the tissue and cellular level. Both bone resorption and bone forma- tion rates are elevated, and the resulting bone loss indicates that resorption exceeds formation (48, 49) . Estrogen replacement therapy decreases bone resorption and prevents bone loss (50, 5 1 ), primarily by suppressing the rate ofremodeling activation (52) . In view of these findings, pharmacological agents that reduce bone resorption and thus bone turnover should have similar effects on the bone loss caused by estrogen deficiency (53) (54) (55) (56) . The aminobisphosphonate ALN is a potent inhibitor of bone resorption in vitro (57) and in vivo (23) (24) (25) (26) (27) . This study examined its efficacy and mode of action in a model that resembles human estrogen deficiency bone loss. ALN was administered intravenously to ensure full delivery, and the 2-wk interval between dosing was based on the estimated duration of the osteoclast resorption phase in the remodeling cycle. In hypercalcemia of malignancy, a single ad- (23) , which shows that 0.1 mg/kg given parenterally every 2 wk is the maximally effective dose in most cases. This dose was bracketed in this study.
The bone changes in ovariectomized baboons were similar to those caused by estrogen deficiency in women. Biochemical markers of bone resorption, serum TRAP, and urinary lysylpyridinoline, a specific degradation product of bone collagen (59), had increased significantly 3 mo after ovariectomy and remained elevated throughout the study. Periodic measurements suggested that peak resorption was reached 9 mo after OVX. Parameters ofbone formation showed similar increases: serum alkaline phosphatase was significantly elevated 3 mo after OVX, and continued to rise at 6 mo, when it leveled offat bone strength (MPa) measured in a core of cancellous core in the L4 vertebra. The findings suggest that ALN treatment suppressed bone turnover to control levels and produced no increasing effects over the 2 yr of treatment, even at the higher ALN dose (corresponding to a 100-mg human oral dose, assuming 1% absorption). p(x2)=0.0034 twofold the non-OVX level. Serum osteocalcin levels were twice as high 6 mo after OVX and remained -1.5-2-fold higher than in non-OVX animals throughout the study, with an apparent decline between 12 and 24 mo in all groups. Each of the five biochemical parameters had sufficient sensitivity to detect increased bone turnover. As previously reported in postmenopausal women, both bone resorption and bone formation increase most during the initial period of estrogen deficiency (60) . In this baboon population, the changes in bone metabolism after ovariectomy occur relatively fast and are more extensive than in postmenopausal women, where estrogen deficiency develops more gradually and occurs at a later biological age. Analysis of iliac crest wedges at 24 mo showed that the parameters of bone turnover were still highly elevated in OVX vehicle-treated animals; the Ac.f was 4.9/yr, compared with 2.0/yr in non-OVX; and the osteoid surface and bone formation rates were also approximately double those in non-OVX animals. ALN decreased bone turnover to non-OVX levels, the effects of the two doses were not significantly different.
Osteoid thickness and MAR increased in the OVX vehicle animals, which was probably a reflection of the large proportion ofnewly formed remodeling sites (61 ) . ALN had no deleterious effect on mineralization, as both MAR and osteoid thickness were maintained at non-OVX levels. In contrast to the 1-yr biopsies (37), the cancellous bone volume in the iliac crest was not significantly different between OVX vehicle and non-OVX. This could be explained by variations in the sampling site ofthe iliac biopsies, shown to be associated with differences in bone volume in humans (62) . Although the bone formation rate at the tissue level (BFR/BS) was significantly increased in untreated OVX animals, the amount of bone formed (mean wall thickness) at the bone multicellular unit (BMU) level was decreased, both in the iliac crest and in the fifth lumbar vertebra (data not shown). These observations suggest that a decrease in the amount of bone made per each remodeling cycle is part of the mechanism of bone loss.
To study the mode of action of ALN at the tissue level in vertebral bone, which cannot be assessed in clinical studies, we also analyzed the L5 vertebra histomorphometrically. Cancellous bone volume was -23% lower in OVX vehicle-treated animals than in non-OVX, but the difference was not statistically significant. ALN treatment, at both doses, increased bone volume above that in non-OVX animals, consistent with the bone mineral density measurements before death.
The increase in cancellous bone volume with ALN treatment was due to an increase in trabecular thickness without changes in trabecular connectivity and correlated with increased strength (see below). These findings are consistent with those of Grynpas et al. (63) , who reported an increase in Tb.Th. and bone strength without changes in connectivity, after administration ofpamidronate in dogs. In agreement with the findings of Meunier and Coupron (64), we found that cancellous bone in the vertebra was significantly lower than in the iliac crest.
As seen in the iliac crest, ALN treatment reduced bone turnover in L5 to control (non-OVX) levels and, even at a multiple of the pharmacological dose, ALN did not abolish bone turnover. As opposed to the iliac crest, MAR and osteoid thickness in L5 were not increased in OVX vehicle baboons. This is consistent with the relatively lower rate of turnover observed in the vertebra, which was about halfthat recorded in the iliac crest. This is also consistent with region-specific differences in bone formation rates reported in human subjects (65) and the estimation by Parfitt (66) that the rate of turnover of cancellous bone in the ilium is -40% per year, compared with -20% in the vertebrae. An interesting observation bearing on the mode ofaction of ALN and probably other aminobisphosphonates is the fact that the number ofosteoclasts, as well as the extent ofthe osteoclast bone interface, were not different among the various groups, suggesting that ALN inhibition ofbone resorption is not due to a reduction in osteoclast number (recruitment) or their attraction to the bone surface. Rather, ALN appears to inhibit osteoclast activity after their interaction with ALN-covered resorption surfaces (67) . These findings are consistent with other similar observations in vivo and in vitro (23, 57, 68) .
The initial changes in BMD, after ovariectomy in baboons, are consistent with similar observations in estrogen-deficient women. BMD in L4 was significantly lower 6 mo after ovariectomy in the OVX untreated vs. non-OVX controls (37) and at 2 yr the difference was -10%. This is in agreement with the findings by Mazess et al. (34) , who reported an -8% reduction in Macaca lumbar BMD 22 mo after OVX. During the 2 yr of study, the lumbar BMD in the non-OVX animals had increased by 9%. In the OVX vehicle group, BMD also increased after 6 mo, when it reached the nadir, and had returned to about initial levels after 2 yr. This could reflect periosteal bone growth. In animals treated with high-dose ALN, BMD was maintained throughout the study at non-OVX levels, while the low-dose ALN had intermediate values between OVX vehicle and non-OVX.
To examine the "quality" ofthe bone accreted as a result of ALN treatment, L4 vertebrae and femora, excised at death, were subjected to ex vivo mechanical testing. Neither ovariectomy nor ALN treatment produced changes in the femora or femoral neck, consistent with the lower turnover of cortical bone, also indicating that ALN present in the bone after 2 yr of treatment had no deleterious effects on the mechanical properties ofcortical bone. Similar findings were obtained after 3 yr of ALN treatment in dogs (69) .
The strength ofa core ofcancellous bone from the L4 vertebra in a compression test increased significantly after 2 yr of treatment with ALN, relative to the OVX vehicle group. A correlation analysis of vertebral strength and bone mineral density (Fig. 3 A) showed that strength increased with the square of the density, similar to the relationship found in human vertebrae obtained from cadavers (70) . These findings demonstrate that the accretion of bone produced by ALN treatment contributed to bone strength, as does normal bone, consistent with the extensive epidemiological evidence showing that fracture incidence is inversely related to BMD (1) (2) (3) (4) (5) (6) (7) (8) .
In conclusion, this study shows that: (a) similar to women, baboons experience increased bone turnover and bone loss after ovariectomy, and (b) continuous ALN treatment for 2 yr normalized bone turnover, prevented the bone loss, and increased vertebral bone strength to control levels.
